<DOC>
	<DOCNO>NCT01368666</DOCNO>
	<brief_summary>The primary objective clinical investigation ass safety effectiveness Perceval S valve 12 month implantation use replace diseased dysfunctional aortic valve aortic valve prosthesis .</brief_summary>
	<brief_title>Safety Effectiveness Study Perceval S Valve Extended CE Mark</brief_title>
	<detailed_description>Primary Endpoints The primary endpoint clinical investigation evaluation safety effectiveness Perceval S valve 12 month implant . The safety Perceval valve assess term percentage incidence mortality morbidity 12 month implant . The effectiveness Perceval valve assess term : - Improvement clinical status mean New York Heart Association ( NYHA ) functional class 12 month implant - Haemodynamic performance echocardiography parameter mean gradient peak gradient , effective orifice area ( EOA ) , effective orifice area indexed ( EOAI ) , performance index , cardiac output , cardiac index degree regurgitation 12 month implant In order determine mortality morbidity , follow specific device related procedure relate adverse event category assess : - valvular thrombosis , thromboembolism , hemorrhage ( whether relate anti coagulant/ antiplatelet drug therapy ) [ major ] , paravalvular leak ( major ) , endocarditis , hemolysis , structural valve deterioration , non structural dysfunction , reoperation ( valve relate ) , explant , death ( valve relate ) , device dislodgement device migration In order assess Haemodynamic performance follow echocardiography parameter measure : - mean gradient peak gradient , effective orifice area ( EOA ) , effective orifice area indexed ( EOAI ) , performance index , cardiac output , cardiac index degree regurgitation Secondary Endpoints The secondary endpoint clinical investigation : - Assessment mortality morbidity rate discharge ( 30 day patient still hospitalize ) 3-6 month implant - Evaluation effectiveness Perceval S valve term improvement clinical status assess mean NYHA functional class discharge ( 30 day patient still hospitalize ) , 3-6 month surgery - Evaluation effectiveness Perceval S valve term haemodynamic performance echocardiography discharge ( 30 day patient still hospitalize ) 3-6 month surgery - Mortality morbidity well haemodynamic parameter assess</detailed_description>
	<criteria>1 . Subjects age &gt; 65 year ; 2 . Subjects aortic valve stenosis stenoinsufficiency ; 3 . Subjects preoperative evaluation indicate need native prosthetic aortic valve replacement biological prosthesis ; 4 . Subjects willing sign inform consent ; 5 . Subjects willing undergo medical followup , echocardiography examination laboratory test plan Study 1 . Subjects involve clinical study drug device ; 2 . Subjects previously implant Perceval S prosthesis , within clinical study , require replacement 3 . Subjects previous implantation valve prostheses annuloplasty ring replace study valve 4 . Subjects require simultaneous cardiac procedure , apart septal myectomy and/or coronary bypass 5 . Subjects require double multiple valve replacement repair mitral , tricuspid , pulmonic valve would replace nonPerceval S valve repair 6 . Subjects aneurysmal dilation dissection ascend aortic wall 7 . Subjects need non elective intervention 8 . Subjects active endocarditis 9 . Subjects active myocarditis 10 . Subjects congenital bicuspid aortic valve 11 . Subjects aortic root enlargement , ratio diameter sinotubular junction annulus diameter , assess TTE , &gt; 1.3 ( see Attachment 1 reference ) 12 . Subjects aortic root height ( measure aortic annulus sinotubular junction ) ≥ 21 mm size 21 , ≥ 22.5 mm size 23 ≥ 24 mm size 25 , ≥ 25 mm size XL/27 13 . Subjects myocardial infarction &lt; 90 day plan valve implant surgery 14 . Subjects know hypersensitivity nickel alloy 15 . The subject document history substance ( drug alcohol ) abuse 16 . The subject prison inmate , institutionalize , unable give inform consent ; 17 . The subject major progressive noncardiac disease , investigator 's experience , result life expectancy short 1 year , implant device produce unacceptable increase risk patient 18 . The subject undergoing renal dialysis chronic renal failure hyperparathyroidism 19 . The subject acute preoperative neurological deficit , myocardial infarction , cardiac event return baseline stabilize ≥ 30 day prior plan valve implant surgery</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Aortic valve replacement</keyword>
	<keyword>Aortic stenosis</keyword>
	<keyword>Biological valve</keyword>
	<keyword>Sutureless valve</keyword>
	<keyword>Stented valve</keyword>
	<keyword>Aortic Valve Disease</keyword>
</DOC>